Wednesday, April 12, 2023 10:49:29 AM
Recent CMND News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/10/2024 08:01:10 PM
- Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product • GlobeNewswire Inc. • 05/10/2024 12:24:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2024 08:01:25 PM
- Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment • GlobeNewswire Inc. • 05/07/2024 11:46:00 AM
- Clearmind Applies to Cease Being a Reporting Issuer in Canada • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders • GlobeNewswire Inc. • 04/17/2024 11:49:00 AM
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders • GlobeNewswire Inc. • 04/10/2024 11:17:00 AM
- Clearmind Medicine CEO Issues Letter to Shareholders • GlobeNewswire Inc. • 04/09/2024 12:07:00 PM
- Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China • GlobeNewswire Inc. • 03/19/2024 11:55:00 AM
- Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial • GlobeNewswire Inc. • 03/13/2024 12:14:00 PM
- Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange • GlobeNewswire Inc. • 03/13/2024 11:30:00 AM
- Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder • GlobeNewswire Inc. • 02/23/2024 12:06:00 PM
- Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China • GlobeNewswire Inc. • 02/05/2024 12:51:00 PM
- Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center • GlobeNewswire Inc. • 02/01/2024 01:15:00 PM
- Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement • GlobeNewswire Inc. • 01/16/2024 04:19:34 PM
- Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement • GlobeNewswire Inc. • 01/11/2024 02:28:00 PM
- Clearmind Medicine Completed Type A Meeting with the FDA • GlobeNewswire Inc. • 01/10/2024 12:18:00 PM
- SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments • GlobeNewswire Inc. • 01/04/2024 12:18:00 PM
- Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments • GlobeNewswire Inc. • 01/04/2024 12:18:00 PM
- Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards • GlobeNewswire Inc. • 12/14/2023 01:26:00 PM
- Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment • GlobeNewswire Inc. • 12/05/2023 01:47:00 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM